ASH Letter to FDA re Draft Guidance on Decentralized Clinical Trials
Citations
ÎÚÑ»´«Ã½. (1).
ASH Letter to FDA re Draft Guidance on Decentralized Clinical Trials.
Retrieved from /advocacy/policy-news-statements-testimony-and-correspondence/testimony-and-correspondence/ash-letter-to-fda-re-draft-guidance-on-decentralized-clinical-trials.
ÎÚÑ»´«Ã½.
"ASH Letter to FDA re Draft Guidance on Decentralized Clinical Trials." Hematology.org.
/advocacy/policy-news-statements-testimony-and-correspondence/testimony-and-correspondence/ash-letter-to-fda-re-draft-guidance-on-decentralized-clinical-trials
(label-accessed December 27, 2024).
"ÎÚÑ»´«Ã½."
ASH Letter to FDA re Draft Guidance on Decentralized Clinical Trials, 27 Dec. 2024 ,
/advocacy/policy-news-statements-testimony-and-correspondence/testimony-and-correspondence/ash-letter-to-fda-re-draft-guidance-on-decentralized-clinical-trials.
